Cargando…

Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma

Drug-induced hypersensitivity syndrome is a rare, severe, and delayed hypersensitivity reaction that may occur with exposure to a number of medications. Typical implicated medications include aromatic anticonvulsants, sulfonamides, minocycline, dapsone, and allopurinol. Bortezomib is a proteasome in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambur, Austin B, Nathoo, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800392/
https://www.ncbi.nlm.nih.gov/pubmed/35141083
http://dx.doi.org/10.7759/cureus.20830
_version_ 1784642249946038272
author Ambur, Austin B
Nathoo, Rajiv
author_facet Ambur, Austin B
Nathoo, Rajiv
author_sort Ambur, Austin B
collection PubMed
description Drug-induced hypersensitivity syndrome is a rare, severe, and delayed hypersensitivity reaction that may occur with exposure to a number of medications. Typical implicated medications include aromatic anticonvulsants, sulfonamides, minocycline, dapsone, and allopurinol. Bortezomib is a proteasome inhibitor and has rarely been associated with cutaneous hypersensitivity reactions. We report a case of recurrent drug-induced hypersensitivity syndrome secondary to bortezomib in a patient with multiple myeloma. The aim of this article is to highlight a unique mediation that may cause drug-induced hypersensitivity syndrome and to emphasize the challenge of managing these patients long-term to prevent relapse of the syndrome.
format Online
Article
Text
id pubmed-8800392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88003922022-02-08 Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma Ambur, Austin B Nathoo, Rajiv Cureus Dermatology Drug-induced hypersensitivity syndrome is a rare, severe, and delayed hypersensitivity reaction that may occur with exposure to a number of medications. Typical implicated medications include aromatic anticonvulsants, sulfonamides, minocycline, dapsone, and allopurinol. Bortezomib is a proteasome inhibitor and has rarely been associated with cutaneous hypersensitivity reactions. We report a case of recurrent drug-induced hypersensitivity syndrome secondary to bortezomib in a patient with multiple myeloma. The aim of this article is to highlight a unique mediation that may cause drug-induced hypersensitivity syndrome and to emphasize the challenge of managing these patients long-term to prevent relapse of the syndrome. Cureus 2021-12-30 /pmc/articles/PMC8800392/ /pubmed/35141083 http://dx.doi.org/10.7759/cureus.20830 Text en Copyright © 2021, Ambur et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Ambur, Austin B
Nathoo, Rajiv
Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title_full Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title_fullStr Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title_full_unstemmed Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title_short Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
title_sort recurrent drug-induced hypersensitivity syndrome following bortezomib for multiple myeloma
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800392/
https://www.ncbi.nlm.nih.gov/pubmed/35141083
http://dx.doi.org/10.7759/cureus.20830
work_keys_str_mv AT amburaustinb recurrentdruginducedhypersensitivitysyndromefollowingbortezomibformultiplemyeloma
AT nathoorajiv recurrentdruginducedhypersensitivitysyndromefollowingbortezomibformultiplemyeloma